Diabetology

Glucose lowering with GLP-1 receptor agonists may reduce the risk for dementia in patients with type 2 diabetes.

Combination therapy with a GLP-1 receptor agonist plus thiazolidinedione significantly reduces the risk for major adverse CV events and death versus nonuse in people with type 2 diabetes.

Although it seems to be a rare complication, there should be a high index of suspicion for colonic ischemia in patients taking a GLP-1 receptor agonist who present with abdominal pain.

A thorough overview of the safety and efficacy of once-weekly basal insulin icodec in type 1 and 2 diabetes, covering pharmacology, pharmacokinetics, adverse effects, drug interactions, and dose recommendations.

Semaglutide increases walking capacity and improves symptoms and quality of life versus placebo in people with type 2 diabetes and peripheral artery disease.

Continuous ranibizumab treatment delivered via the Port Delivery System is comparable to monthly injections for improving vision in patients with diabetic eye disease.

Discover the growing evidence for incretin-based therapies in metabolic dysfunction-associated steatohepatitis, the potential mechanisms involved, common side effects, and what’s needed to finesse their use.

Oral semaglutide significantly reduces the risk for major adverse cardiovascular events versus placebo in people with high-risk type 2 diabetes.

Dapagliflozin significantly reduces the urine albumin-to-creatinine ratio versus placebo in people with type 2 diabetes and chronic kidney disease, but the magnitude of the effect varies per person.

Discover the genetic risk loci that influence both type 2 diabetes and CVD, and how disease-specific subtyping approaches may help reduce the burden of multimorbidity in type 2 diabetes.

Weight loss of 10% or more within 5 years of type 2 diabetes diagnosis improves HbA1c and cardiometabolic parameters, and increases remission rates versus less weight loss.

NICTH was diagnosed in a man with pelvic sarcoma. Severe hypoglycemia did not respond to standard treatments but had a partial response to rhGH and angioembolization of the tumor.

Combination therapy is a cornerstone of type 2 diabetes management, but what’s known about the effects of combining SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs?

Shorter sleep duration and both regular and occasional snoring are linked to an increased risk for type 2 diabetes in women with a history of gestational diabetes.

Imaging techniques are enhancing our understanding of the myocardial microcirculation and providing insights into the early stages of microvascular dysfunction in people with diabetes.

Increased risk for nonarteritic anterior ischemic optic neuropathy associated with semaglutide treatment in people with type 2 diabetes is not as great as previously reported.

Berberine ursodeoxycholate, a gut–liver anti-inflammatory metabolic modulator, significantly reduces HbA1c and improves hepatic and cardiometabolic parameters in people with type 2 diabetes.

Recommendations proposed to reduce glycemic variability and improve glycemic management in people with type 1 diabetes, focusing on physical activity, dietary habits, insulin therapy, and other causes of increased variability.

Complete heterozygous deletion of HNF1B was incidentally discovered in a woman who was enrolled in a clinical trial for type 1 diabetes and received immunosuppressive treatment for 4 years when she was a child.

Obesity treatments can cause a large decline in muscle mass. How can this be addressed in people with type 2 diabetes who already experience accelerated loss of muscle mass and function?